Research summary
Interleukin-1 family biology and clinical inflammation drive this work. A 2009 Annual Review of Immunology piece synthesized the immunological and inflammatory functions of the IL-1 family, organizing the eleven members by receptor usage and downstream signaling and highlighting the homology of the IL-1R cytoplasmic domain with the Toll-IL-1 receptor (TIR) domain shared by Toll-like receptors, which unifies sterile and infectious inflammation under a common signaling framework [1]. A 2011 Blood paper covered IL-1 in the pathogenesis and treatment of inflammatory diseases, organizing autoinflammatory syndromes (cryopyrinopathies, familial Mediterranean fever) and acquired conditions (gout, type 2 diabetes, atherosclerosis) by their IL-1 dependence and reviewing clinical experience with anakinra, rilonacept, and canakinumab [3]. A 2017 Immunological Reviews piece on the IL-1 family in innate and acquired immunity extended the framework to incorporate IL-18, IL-33, IL-36, IL-37, and IL-38 with their distinct activating proteases and decoy receptors [5]. A 1986 Journal of Immunology paper characterized the cell-surface glycoprotein ICAM-1 originally defined by a leukocyte-aggregation-inhibiting monoclonal antibody, showed its tissue distribution and induction by IL-1 and IFN-γ, and established ICAM-1 as a key cytokine-regulated adhesion molecule in inflammatory recruitment [2]. A 1988 NEJM paper detected circulating tumor necrosis factor in plasma after endotoxin administration in healthy volunteers using a sensitive bioassay, providing direct evidence that TNF mediates the host response to bacterial endotoxin and laying groundwork for anti-TNF therapy [6]. A 1989 NEJM paper showed that dietary supplementation with n-3 fish-oil fatty acids reduced IL-1 and TNF synthesis by mononuclear cells, providing a mechanistic basis for the anti-inflammatory effects of marine omega-3 intake [4]. The works thus chart the evolution of cytokine biology from initial bioassays to a comprehensive IL-1-family framework and targeted therapeutics.
Recent publications
- Neuroinflammation in Alzheimer's diseaseDOI
- Immunological and Inflammatory Functions of the Interleukin-1 FamilyDOI
- Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).DOI
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesDOI
- Proinflammatory CytokinesDOI
- The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear CellsDOI
- The Interleukin-1 Family: Back to the FutureDOI
- Overview of the IL‐1 family in innate inflammation and acquired immunityDOI
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesDOI
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email Charles A. Dinarello 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0002-5073-8316
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, The University of Tokyo faculty directory). Last refreshed 2026-05. Report incorrect information.